Physician profile
Tara Lynd
NPI 1558378653
$2,230.98
in general payments reported to CMS, 2019-2025
26 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $184 · 2021: $488 · 2022: $181 · 2023: $550 · 2024: $443 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,217.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $389.21 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $388.79 | 2019-2025 | |
| Corium, LLC | $173.32 | 2021-2024 | Azstarys |
| Tris Pharma INC | $157.89 | 2020-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $137.88 | 2020-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Seqirus USA INC | $105.72 | 2022-2024 | Flucelvax, Flucelvax Quadrivalent |
| Sanofi Pasteur INC. | $84.85 | 2019-2025 | |
| Kaleo, INC. | $77.32 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $73.35 | 2023-2025 | |
| Alk-Abello, INC | $71.28 | 2023-2024 | Ragwitek, Odactra, Grastek |
| Sobi, INC | $69.35 | 2019-2024 | |
| Ultragenyx Pharmaceutical INC. | $59.43 | 2020-2023 | |
| Verrica Pharmaceuticals INC. | $59.41 | 2024-2025 | Ycanth |
| Nestle Healthcare Nutrition INC. | $55.23 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $49.57 | 2023-2024 | Flumist Quadrivalent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $45.91 | 2020-2021 | |
| Biomarin Pharmaceutical INC. | $38.22 | 2024-2025 | Voxzogo 1.2mg |
| Sage Therapeutics, LLC | $26.15 | 2021 | |
| Ironshore Pharmaceuticals INC. | $25.65 | 2019 | |
| Abbvie INC. | $24.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.78 | 2019 | |
| Acadia Pharmaceuticals INC | $19.89 | 2024 | Daybue |
| Shire North American Group INC | $19.83 | 2019 | |
| Mylan Pharmaceuticals INC. | $19.36 | 2021 | |
| Sarepta Therapeutics, INC. | $19.34 | 2020 | |
| Alexion Pharmaceuticals, INC. | $15.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Lynd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.